Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer

Table 2 Treatment data

	Total, n = 94 (%)
ADT
GnRH and nonsteroidal antiandrogen	82 (87)
GnRH alone	9 (10)
Orchidectomy	3 (3)
ADT
Time from ADT start to Docetaxel start, days
Median (range)	63 (8-400)
ADT duration, days
Median (range)	331 (5-1038)
Docetaxel
751 mg/m²	77
Adm mean dose % of full dose	91
Mean adm dose, mg	139
Mean acc dose, mg	758
Completed all cycles	63 (67)
502 mg/m²	8
Adm mean dose % of full dose	83
Mean adm dose, mg	86
Mean acc dose, mg	610
Completed all cycles	4 (50)
Switch	9
Adm mean dose % of full dose	87
Mean adm dose, mg	107
Mean acc dose, mg	641
Completed all cycles	9 (100)
Dose reduction	33 (35)
Dose escalation	13 (14)
Unchanged	47 (50)
Missing	1 (1)
Best response at end of Docetaxel3
CR	6 (6)
PR	50 (53)
SD	15 (16)
PD	11 (12)
NE	12 (13)
Est. PFS	Mean (95%CI)
12 mo
CHAARTED/STAMPEDE	75% (66-84)
Swedish national guidelines	71% (61-81)
24 mo
CHAARTED/STAMPEDE	58% (46-70)
Swedish national guidelines	55% (43-67)
OS
12 mo	93% (87-99)
24 mo	86% (76-96)

¹75 mg/m² is given in 6 cycles every 21 d.

²50 mg/m² is given in 9 cycles every 14 d.

³CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease. (PD definition CHAARTED: Serologic increase of PSA level of more than 50% above nadir reached after initiation of androgen deprivation therapy, two consecutive increases at least 2 wk apart. If the nadir was less than 2 μg/L, a minimum increase of more than 2 μg/L was required. STAMPEDE: Biochemical progression rose by 50% above the within 24-wk nadir and above 4 μg/L. Radiologic according to RECIST version 1.0 Swedish national guidelines: Clinical: Increasing symptoms or deterioration of general condition. Serologic ≥ 25 percent from lowest PSA value after start of latest given treatment an augmentation of at least ≥ 2 μg/L is required. Radiologic progression of existing or new metastasis).

NE: Nonevaluable; ADT: Androgen deprivation therapy; PFS: Progression-free survival.